- Home
- LFMD vs RIGL Comparison
LFMD vs RIGL Comparison
Compare LFMD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFMD
- RIGL
- Stock Information
- Founded
- LFMD 1994
- RIGL 1996
- Country
- LFMD United States
- RIGL United States
- Employees
- LFMD N/A
- RIGL N/A
- Industry
- LFMD Medical/Nursing Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LFMD Health Care
- RIGL Health Care
- Exchange
- LFMD Nasdaq
- RIGL Nasdaq
- Market Cap
- LFMD 330.5M
- RIGL 335.5M
- IPO Year
- LFMD N/A
- RIGL 2000
- Fundamental
- Price
- LFMD $6.66
- RIGL $29.70
- Analyst Decision
- LFMD Buy
- RIGL Buy
- Analyst Count
- LFMD 6
- RIGL 5
- Target Price
- LFMD $12.50
- RIGL $38.20
- AVG Volume (30 Days)
- LFMD 1.2M
- RIGL 668.8K
- Earning Date
- LFMD 11-06-2025
- RIGL 11-06-2025
- Dividend Yield
- LFMD N/A
- RIGL N/A
- EPS Growth
- LFMD N/A
- RIGL N/A
- EPS
- LFMD N/A
- RIGL 5.43
- Revenue
- LFMD $245,563,670.00
- RIGL $267,921,000.00
- Revenue This Year
- LFMD $21.50
- RIGL $59.93
- Revenue Next Year
- LFMD $17.41
- RIGL N/A
- P/E Ratio
- LFMD N/A
- RIGL $5.32
- Revenue Growth
- LFMD 37.74
- RIGL 105.62
- 52 Week Low
- LFMD $3.99
- RIGL $13.57
- 52 Week High
- LFMD $15.84
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- LFMD 50.32
- RIGL 41.29
- Support Level
- LFMD $6.42
- RIGL $27.75
- Resistance Level
- LFMD $7.32
- RIGL $29.46
- Average True Range (ATR)
- LFMD 0.33
- RIGL 1.51
- MACD
- LFMD 0.14
- RIGL -0.40
- Stochastic Oscillator
- LFMD 48.37
- RIGL 29.10
About LFMD LifeMD Inc.
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.